These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 36882990)

  • 21. The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib.
    Richardson PG; Laubach JP; Schlossman RL; Ghobrial IM; Redman KC; McKenney M; Warren D; Noonan K; Lunde L; Doss D; Colson K; Hideshima T; Mitsiades C; Munshi NC; Anderson KC
    Eur J Haematol; 2012 May; 88(5):446-9. PubMed ID: 22300348
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial.
    Landgren O; Hultcrantz M; Diamond B; Lesokhin AM; Mailankody S; Hassoun H; Tan C; Shah UA; Lu SX; Salcedo M; Werner K; Rispoli J; Caple J; Sams A; Verducci D; Jones K; Concepcion I; Ciardello A; Chansakul A; Schlossman J; Tavitian E; Shekarkhand T; Harrison A; Piacentini C; Rustad EH; Yellapantula V; Maclaughlan K; Maura F; Landau HJ; Scordo M; Chung DJ; Shah G; Lahoud OB; Thoren K; Murata K; Ramanathan L; Arcila ME; Ho C; Roshal M; Dogan A; Derkach A; Giralt SA; Korde N
    JAMA Oncol; 2021 Jun; 7(6):862-868. PubMed ID: 33856405
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Complete remission and early relapse of refractory plasma cell leukemia after bortezomib induction and consolidation by HLA-mismatched unrelated allogeneic stem cell transplantation.
    Krüger WH; Kiefer T; Schüler F; Lotze C; Busemann C; Dölken G
    Onkologie; 2007 Apr; 30(4):193-5. PubMed ID: 17396042
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of VRD(Bortezomib, Lenalidomide, and Dexamethasone) Consolidation Therapy and Maintenance Therapy with Immunomodulatory Drugs(Thalidomide or Lenalidomide) after Autologous Peripheral Blood Stem Cell Transplantation in the Era of Bortezomib-Containing Induction Therapy-A Single Institution Experience.
    Tanimura A; Hirai R; Nakamura M; Takeshita M; Togano T; Sekine R; Hagiwara S; Miwa A
    Gan To Kagaku Ryoho; 2020 May; 47(5):789-796. PubMed ID: 32408321
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessing Pretransplant and Posttransplant Therapy Response in Multiple Myeloma Patients.
    Potre C; Borsi E; Potre O; Samfireag M; Costachescu D; Cerbu B; Bratosin F; Secosan C; Negrean RA
    Curr Oncol; 2022 Nov; 29(11):8501-8512. PubMed ID: 36354730
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Treatment of early relapsed plasma cells leukemia after unrelated bone marrow transplant with KRD (carfilzomib, lenalidomide and dexamethasone): a case report.].
    Palazzo G
    Recenti Prog Med; 2020 Mar; 111(3):160-166. PubMed ID: 32157264
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Lenalidomide induced therapeutic response in a patient with aggressive multi-system Langerhans cell histiocytosis resistant to 2-chloro-deoxyadenosine and early relapsing after high-dose BEAM chemotherapy with autologous peripheral blood stem cell transplantation].
    Adam Z; Rehák Z; Koukalová R; Szturz P; Krejčí M; Pour L; Zahradová L; Moulis M; Kodet R; Nebeský T; Brejcha M; Adamová Z; Hájek R; Mayer J
    Vnitr Lek; 2012 Jan; 58(1):62-71. PubMed ID: 22448704
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A case of allogeneic hematopoietic stem cell transplantation for primary plasma cell leukemia after treatment with daratumumab.
    Horisawa Y; Kondo T; Hishizawa M; Yamashita K; Takaori-Kondo A
    Ann Hematol; 2020 Nov; 99(11):2699-2701. PubMed ID: 32318778
    [No Abstract]   [Full Text] [Related]  

  • 29. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management.
    Rajkumar SV
    Am J Hematol; 2020 May; 95(5):548-567. PubMed ID: 32212178
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia.
    Tabchi S; Nair R; Kunacheewa C; Patel KK; Lee HC; Thomas SK; Amini B; Ahmed S; Mehta RS; Bashir Q; Qazilbash MH; Weber DM; Orlowski RZ; Alexanian R; Feng L; Manasanch EE
    Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):560-569. PubMed ID: 31201134
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma.
    Salwender H; Bertsch U; Weisel K; Duerig J; Kunz C; Benner A; Blau IW; Raab MS; Hillengass J; Hose D; Huhn S; Hundemer M; Andrulis M; Jauch A; Seidel-Glaetzer A; Lindemann HW; Hensel M; Fronhoffs S; Martens U; Hansen T; Wattad M; Graeven U; Munder M; Fenk R; Haenel M; Scheid C; Goldschmidt H
    BMC Cancer; 2019 May; 19(1):504. PubMed ID: 31138244
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A successful case of venetoclax-based therapy in relapsed/refractory secondary plasma cell leukemia.
    Kupsh A; Arnall J; Voorhees P
    J Oncol Pharm Pract; 2020 Jul; 26(5):1274-1278. PubMed ID: 31865846
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Successful bortezomib/dexamethasone induction therapy with lenalidomide in an elderly patient with primary plasma cell leukemia complicated by renal failure and pulmonary hypertension.
    Tamura S; Koyama A; Shiotani C; Kurihara T; Nishikawa A; Okamoto Y; Fujimoto T
    Intern Med; 2014; 53(11):1171-5. PubMed ID: 24881743
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successful treatment with bortezomib-containing regimen of primary plasma cell leukemia: a case report.
    Obeidat MB; Al-Swailmeen AM; Arabeat AM; Abukamar AS
    Pan Afr Med J; 2020; 36():15. PubMed ID: 32774592
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The efficacy and safety of modified bortezomib-lenalidomide-dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma.
    Okazuka K; Ishida T; Nashimoto J; Uto Y; Sato K; Miyazaki K; Ogura M; Yoshiki Y; Abe Y; Tsukada N; Suzuki K
    Eur J Haematol; 2020 Feb; 104(2):110-115. PubMed ID: 31733155
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bone formation following lenalidomide-dexamethasone combination therapy in cases of multiple myeloma refractory to high-dose chemotherapy with bortezomib and autologous peripheral blood stem cell transplantation: report of a case and review of the literature.
    Sekiguchi Y; Ichikawa K; Wakabayashi M; Sugimoto K; Tomita S; Izumi H; Nakamura N; Sawada T; Ohta Y; Komatsu N; Noguchi M
    Int J Clin Exp Pathol; 2015; 8(8):9609-19. PubMed ID: 26464727
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Short Course of Post-Transplantation Cyclophosphamide and Bortezomib for Graft-versus-Host Disease Prevention after Allogeneic Peripheral Blood Stem Cell Transplantation Is Feasible and Yields Favorable Results: A Phase I Study.
    Al-Homsi AS; Cole K; Bogema M; Duffner U; Williams S; Mageed A
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1315-20. PubMed ID: 25765556
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Treatment of AL-amyloidosis--results from one clinic and review of published experience with new agents (bortezomib, thalidomide and lenalidomide) in AL-amyloidosis].
    Adam Z; Pour L; Krejcí M; Zahradová L; Krivanová A; Mardová J; Kovárová L; Stepánková S; Moulis M; Kren L; Veselý K; Svobodová I; Germáková Z; Nedbálková M; Mayer J; Hájek R
    Vnitr Lek; 2010 Mar; 56(3):190-209. PubMed ID: 20394205
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful treatment of primary plasma cell leukaemia by allogeneic stem cell transplantation from haploidentical sibling.
    Nonami A; Miyamoto T; Kuroiwa M; Kunisaki Y; Kamezaki K; Takenaka K; Harada N; Teshima T; Harada M; Nagafuji K
    Jpn J Clin Oncol; 2007 Dec; 37(12):969-72. PubMed ID: 18055567
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of Induction With VCD Versus VRD on the Outcome of Patients With Multiple Myeloma After an Autologous Hematopoietic Stem Cell Transplantation.
    Afrough A; Pasvolsky O; Ma J; Srour S; Bashir Q; Saini N; Hosing C; Popat UR; Kebriaei P; Delgado R; Ullah MR; Murphy R; Manasanch EE; Lee HC; Kaufman GP; Patel KK; Thomas SK; Weber DM; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH
    Transplant Cell Ther; 2022 Jun; 28(6):307.e1-307.e8. PubMed ID: 35331973
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.